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Abstract  
Background: Pharmaceutical expenditure has grown by 16% per annum in China, enhanced 
by incentives for physicians and hospitals. Hospital pharmacies dispense 80% of medicines in 
China, accounting for 46% of total hospital expenditure. Principal measures to moderate drug 
expenditure growth include pricing initiatives as limited demand-side measures. Objective: 
Assess current utilization and expenditure including traditional Chinese medicines (TCMs) 
between 2006 and 2012. Methods: Uncontrolled retrospective study of medicines to treat 
cardiovascular and cerebrovascular (CV) diseases in one of the largest hospitals in Southwest 
China. Results: Utilisation increased 3.3 fold for CV medicines, greatest for TCMs, with 
expenditure increasing 4.85 fold. Low prices for generics were seen, similar to Europe. 
However, there was variable utilization of generics at 29% to 31% of total product volumes in 
recent years. There continued to be irrationality in prescribing with high use of TCMs, and 
utilization of medicines dropping significantly once low prices. Conclusion: Prices still have an 
appreciable impact on utilization in China. Potential measures similar to those implemented 
among Western European countries could improve rationality and conserve resources. 
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Background 
 
There are ongoing initiatives across countries to improve prescribing efficiency. This is due to 
continual pressure on resources brought about by ageing populations and the continued 
launch of new premium priced drugs [1-5]. Initiatives for established drugs include multifaceted 
demand-side measures to increase the prescribing of low costs generics versus originators 
and patented products in a class [2-8]. Classes include the proton pump inhibitors (PPIs), 
statins and the renin-angiotensin inhibiting drugs, with the latter including both angiotensin 
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) [2-7,9-17]. 
The combination of low-cost generics and mutlifaceted demand-side measures has resulted in 
considerable savings in some European countries without compromising care [2-4,7,9,10]. 
 
As a developing and transitional country, China has also seen rapid growth in pharmaceutical 
expenditure, with growth averaging 16% per annum during the past decade [18]. This growth 
has been enhanced by increasing health insurance coverage, now covering 90% of the 
Chinese population [18,19], with the ultimate goal of universal coverage by 2020 [18,20-25]. A 
number of measures and initiatives have been introduced in China in recent years to try and 
moderate growth rates to help achieve universal coverage as well as help address the 
difficulties with seeing physicians and associated costs. These include cutting pharmaceutical 
prices, introducing essential medicine lists and guidelines and establishing co-payment caps 
[18-21,24-27]. Having said this, there appear to be currently no universal measures among 
public insurers to monitor the quality of physician prescribing illustrated for instance by the 
continued high use of antibiotics and injectables [26, 28-32]. Pharmaceutical expenditure has 
been a principal target in China since it accounts for 46% of total hospital expenditure in 2010 
[18], with KRVSLWDOSKDUPDFLHVGLVSHQVLQJPRUHWKDQRIWKHFRXQWU\¶VWRWDOPHGLFLQHs 
[18,26, 27,33]. Out-of-pocket payments account for 36% of total healthcare expenditure [21]. 
The principal reasons for the high level of dispensing in hospitals include patient convenience, 
physician recommendations, the possibility of nonstandardized prescriptions and a greater 
assurance of pharmaceutical quality [26].  
 
Drug prices are currently determined by the government (state or province) or manufacturers 
themselves, with actual prices subject to tenders in each province or municipality orchestrated 
by the local health departments [18, 19, 26]. Since 2006, the margin between the procured and 
retail price was fixed to approximaely15%.  As a result, greatly standardizing the purchasing 
channels among Chinese hospitals [19,2627, 33]. For most pharmaceuticals, government 
control and tendering are the principal forces to decrease prices. Market forces are enhanced 
by appreciable competition among generic companies, with more than 5,000 pharmaceutical 
manufacturers in China producing mainly generics [18]. However, there are still no formal 
pricing mechanisms for generics in China unlike the situation in Europe, which helped achieve 
generic prices as low as 2% to 10% of patent prices in some countries [2-5,7,14,16]. The 
current system in China also encourages physicians to
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as prescribe those that provide the greatest profit to enhance their income. Hospitals also rely 
on revenues from medicines for their sustainability. This combination subsequently influences 
prescribing patterns [18,19,26, 32-35]. Lim and colleagues also found that dispensing doctors 
prescribed more medicines to patients, and prescribed more originators than generic drugs 
[36]. This is not helped by similar patient co-payments for an originator or generic. As a result, 
little increase in the use of generics in China was noted in recent years [18]. 
 
Medicines to treat cardiovascular and cerebrovascular diseases are important classes in 
China due to the increasing incidence and prevalence of these diseases [18]. This includes 
oxiracetam, which is perceived to improve learning and memory functions of patients with 
dementia. Jin and colleagues also recently identified cardiovascular drugs among the leading 
therapeutic classes by volume among hospitals in the Chongqing District of China, alongside 
anti-infective agents and medicines for the digestive and nervous systems [37], with its 
population of 28.8 million people (2010 census). This is similar to other districts in China [38]. 
This also includes over 110 traditional Chinese medicines (TCMs) used to treat these 
conditions despite increasing awareness of the safety problems associated with TCMs in 
recent years [39,40]. TCMs generally contain yellow pigment from Carthamine or salvianolic 
acids, and are typically administered via injections. New TCMs continue to be made available 
with the active components containing for example ginseng, the root of red-rooted salvia, red 
ginseng, Folium Ginkgo, pseudo-ginseng and Erigeron breviscapus extract. The 
manufacturers of these typically apply for new medicine approval. As a result, gain exclusive 
approval for manufacturing which helps obtain higher procurement prices. This use of 
traditional medicines is despite attempts to develop guidelines and essential medicine lists in 
China based on published evidence; enhanced by the increased profitability from injections 
[18,21,29,31].  
 
The prices of cardiovascular drugs have been adjusted four times between 2006 and 2012 in 
Chongqing District. There were two changes with tendering, in March 2006 and April 2011, 
and two national adjustments to the maximum retail prices, in January 2007 and March 2011 
[41]. However, there are still considerable incentives for physicians to prescribe expensive 
originators rather than cheaper generics despite initiatives to enhance INN (International 
Non-proprietary name) prescribing [18,26,29,33,42]. 
 
Consequently, the aims of this study are to firstly to assess changes in the utilisation patterns 
of cardiovascular and cerebrovascular drugs in recent years, including traditional Chinese 
medicines, with increasing availability of generic drugs. Secondly, assess changes in the 
utilisation of selected originator and generic cardiovascular and cerebrovascular drugs over 
time including TCMs as well as potential factors leading to these patterns. Thirdly, assess 
changes in cardiovascular and cerebrovascular drug expenditure over time as well as changes 
in the procurement prices for generic, originator drugs and traditional Chinese medicines. This 
includes the influence of price reductions as well as potentially increasing competition as more 
generics become available. Lastly, suggest potential future reforms that China could consider 
to enhance the rational use of medicines as well as obtain further price reductions. 
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Methods 
 
This was an observational uncontrolled retrospective study of prescriptions between 2006 and 
2012 [43]. This methodology was chosen since there have been multiple supply- and 
demand-side measures in China and its various Districts during this period making it difficult to 
perform an interrupted time series analysis. However where possible, we have performed 
simple statistical analyses such as the chi-square test.  
 
We will firstly describe why we chose this data set for analysis before describing the 
methodology chosen for assessing utilisation and expenditure data.  
 
Typically for drug utilisation analyses, data is obtained from health authorities or pharmacy 
databases [2-7,9,10,12-16]. However in China, most drug utilisation studies are performed 
with data from hospitals as they incorporate both inpatient and outpatient data [18,39]. In 
addition, as mentioned, they account for 80% of total drugs currently dispensed in China 
[18,26,33]. Consequently, hospital procurement data is currently an optimal source of drug 
utilisation data in China.  Accurate data on hospital tendering and procurement is especially 
important for this type of analysis given the profitability from medicines [29]. This data is not 
always available from some commercial sources, which can just provide maximum retail price 
data [33]. In addition, hospitals in China also procure and dispense medicines which are not 
included in the current reimbursement list. Consequently, comprehensive utilization and 
expenditure would not be picked up through analyzing reimbursed data sets from the 
Insurance Department. 
 
&KRQJTLQJLVDPXQLFLSDOLW\GLUHFWO\XQGHU&KLQD¶VFHQWUDOJRYHUQPHQt. In the urban district in 
Chongqing City, the main public general hospitals include three hospitals affiliated to the Third 
Military Medical University, two hospitals affiliated to Chongqing Medical University, and 10 
municipal hospitals. Every hospital may include different generic drugs, but with the same 
originator equivalents as part of the tendering process to obtain good prices [18]. 
 
We chose the largest hospital in Chongqing District to conduct our study as it is one of the 
largest hospitals in Southwest China. It can also provide comprehensive datasets on both 
utilization and expenditure and is a typical health care provider. The dataset was obtained from 
the magazine company of China Pharmacy. The company is located in Chongqing and is able 
to collect detailed information from large hospitals in southwest China. The data contains all 
individual drug information including product names, purchase dates, dosage forms, 
specification, manufacturers, unit prices and volumes. This is an authoritative source for drug 
utilisation statistics in China, which is regularly audited. We used a similar approach in 
previous studies [18].  
 
The datasets are broken down into three groups: 
x Originator products. These include products from multinational companies imported into 
China or manufactured by joint ventures in China founded by multinational pharmaceutical 
companies. Since these medicines have the original intellectual property and are 
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considered by some to have better quality, they typically command a premium prices 
versus generics 
x Generic products. These are produced by enterprises with local investment, including 
state-owned and private enterprises. Prices are influenced by the Chinese price control 
policy, and these products typically face competition from a number of different 
manufacturers. Their quality has improved in recent years with a number of different 
measures to enhance manufacturing standards. For instance in 2009, all medicines on the 
Chinese essential medicine list were required to undergo quality sampling and testing at 
the provincial level at least annually and at the central level at least every three years [21]. 
Good Manufacturing (GMP) standards were also revised in 2011 to further improve the 
quality of generic manufacturing in China [21] 
x Traditional Chinese medicines. Usually prepared from herbs or other traditional 
sources, with some preparations involve chemical substances. The main delivery route is 
via an injection. The characteristics of traditional Chinese medicines are multi target and 
multi utility. They are believed to provide comprehensive treatment of patients with chronic 
cardiovascular and cerebrovascular diseases enhanced by a high degree of acceptance 
among both physicians and patients. They are also believed for instance to improve blood 
circulation and remove blood stasis and activate collaterals [37]. 
 
Volume data was derived from the quantity of drugs dispensed as we considered procurement 
volume equal to clinical consumption. We chose unit package data as our measurement of 
utilisation, e.g. one box (e.g., 10 mg × 16) or one bottle (e.g., 0.1 g × 1 ml for an injection or 1g 
for powder) as opposed to defined daily doses (DDDs) [44]. This is because: 
x there is currently no reliable source for DDDs for traditional Chinese medicines (the 
principal products used) with several authors using different methodologies and figures in 
their calculations [39] 
x most prescribing physicians in China use the package unit (i.e., one box or one bottle) as 
WKHFKDUJLQJXQLWZKHQFDOFXODWLQJWKHLUSDWLHQWV¶H[SHQGLWXUH This is a similar concept to 
prescription items in the UK, which is a key metric among UK primary care organisations 
[16] 
x the specifications of the products typically did not change during the study period  
 
Calculations to determine procurement prices, prices per unit and overall expenditure were 
based on Chinese currency yuan (CNY). There was no allowance for inflation or deflation as 
we wanted to compute actual changes over time as a result of the tendering process. This is in 
line with previous studies [2-7,9,10,12-16]. We have also not converted CNY data to either 
US$ or Euros during the course of the study as we did not want the pricing data influenced by 
currency fluctuations, especially during the recent financial crises in Europe and the US. 
 
In addition to overall utilisation and expenditure data, we also analysed several individual 
products separately to improve our understanding of the situation in China. For this, we 
typically chose to analyse in detail individual products with an average purchase volume of 
1,000 packs per month or a procurement price higher than CNY 20, or a total annual value 
over CNY 1 million.  
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Results 
 
Utilisation (general) 
 
Total utilisation of drugs to treat cerebrovascular and cardiovascular diseases increased 3.3 
fold between 2006 and 2012, rising from 1.2 million units in 2006 to 3.98 million units in 2012 
(Figure 1). This included both single agents and combinations, and was greatest for traditional 
Chinese medicines at 4.41 fold (Figure 1). Utilisation increased among all product groups 
apart from ligustrazine. The increase was highest for the statins and the renin-angiotensin 
inhibiting drugs (Table 1). 
 
Figure 1 ± Overall growth in utilisation of the three main categories (by Units) 2006 to 2012 in 
the Chongqing District 
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TCM = Traditional Chinese Medicines 
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Table 1 ± Utilisation of different pharmacotherapeutic groups and traditional Chinese 
medicines (by unit) in the Chongqing District 2006 to 2012 
 
Product/Group 
Total utilisation 
2006 
Total utilisation 
2012 
Increase (2012 
vs. 2006) 
Beta blockers (including 
combinations) 
45253 181208  4.0 fold 
Calcium channel blockers 
(including combinations) 
66098 286700 4.34 fold 
Renin-angiotensin 
inhibitor drugs 
(including 
combinations) 
ACEIs 51782 74665 1.44 fold 
ARBs 25662 288160 11.23 fold 
Statins 25765 214799 8.34 fold 
Ligustrazine 40119 0 0 
Levocarnitine 40874 76773 1.88 fold 
Oxiracetam 33390 139626 4.18 fold 
Cinepazide 25600 36780 0.44 fold 
Others (consolidated ) 379869 610092 1.61 
Total traditional Chinese 
medicines 
464954 2048258 4.41 fold 
Total 1199366 3957061 3.30 fold 
NB Ligustrazine is included separately although it may also be considered a Chinese herbal medicine. 
Utilisation measured in package units. Fold = times, e.g.4.0 fold = 4 times  
 
Analysis of the 12 single products meeting our definition showed an increase in the utilisation 
of both originators and generics. However, there was variable utilisation of generics with 
overall utilisation stabilising at 29% to 31% of total utilisation for these 12 cardiovascular 
products in recent years (Table 2. Table 1A in the Appendix contains more detailed analysis - 
broken down by 6 month periods). 
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Table 2 ± Yearly utilisation of both generics and originators for 12 single cardiovascular and 
cerebrovascular products in the Chongqing District between 2006 to 2012 
 
Product 2006 2007 2008 2009 2010 2011 2012
Metoprolol - Generic 0 0 0 0 0 0 0
Metoprolol - Originator 22637 28302 33680 37920 46080 64150 102240
%LVRSURORO±*HQHULF 0 0 0 0 0 0 0
Bisoprolol - Originator 8400 14040 18300 17605 34380 36720 40860
$PORGLSLQH±*HQHULF 9445 17170 21200 34150 47570 60608 66510
$PORGLSLQH±2ULJLQDWRU 7900 8900 9600 19466 26200 25700 41850
1LIHGLSLQH±*HQHULF 25259 26128 28500 28430 27100 29600 17100
1LIHGLSLQH±RULJLQDWRU 11880 18650 31621 25380 39330 37170 55620
)HORGLSLQH±*HQHULF 248 1120 1080 1050 940 250 1240
)HORGLSLQH±2ULJLQDWRU 2640 6670 12557 19680 29844 36160 53280
%HQD]HSULO±*HQHULF 0 329 1730 3380 14810 12940 15600
Benazepril - Originator 6480 8560 11280 16560 17640 25020 30899
/RVDUWDQ±*HQHULF 0 0 0 0 0 0 4600
/RVDUWDQ±2ULJLQDWRU 6160 10990 17800 23330 38600 36200 37620
7HOPLVDUWDQ±*HQHULF 252 1500 5312 5600 7600 9800 11175
7HOPLVDUWDQ±2ULJLQDWRU 1582 3587 8400 8930 11600 14848 26200
9DOVDUWDQ±*HQHULF 814 1200 400 1050 1200 1300 1725
9DOVDUWDQ±2ULJLQDWRU 1766 4250 14409 21030 24000 40140 58880
$WRUYDVWDWLQ±*HQHULF 7680 8400 8958 11760 27659 57520 89793
$WRUYDVWDWLQ±2ULJLQDWRU 1920 2520 5339 20800 31440 34160 42282
6LPYDVWDWLQ±*HQHULF 384 396 2052 4716 4420 3200 1680
6LPYDVWDWLQ±2ULJLQDWRU 7210 15604 31400 34320 63800 60800 38600
,UEHVDUWDQ±*HQHULF 0 700 11300 18600 25735 19800 25000
,UEHVDUWDQ±2ULJLQDWRU 6650 11500 12686 20520 32920 34200 43200 NB. 
Utilisation measured in package units 
 
Procured expenditure (general) 
 
Total procurement expenditure on cardiovascular and cerebrovascular medicines increased 
from 30.76million CNY to 149.29 million, a 4.85-fold increase over the 7 years, representing a 
compounded annual growth rate of 30% (Figure 2). There was increasing expenditure on 
traditional Chinese medicines, with their share of total expenditure increasing from 35% in 
2006 to 57% in 2012. 
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Figure 2 - Total procurement expenditure on cardiovascular and cerebrovascular medicines in 
CNY in the Chongqing District 2006 to 2012 
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There was also steady growth in procurement expenditure of originator products with 
procurement values of more than one million CNY in 2012 (Figure 3). 
 
Figure 3 ± Total procurement expenditure of the 12 originator cardiovascular and 
cerebrovascular medicines in CNY in the Chongqing District 2006 to 2012 
0
500000
1000000
1500000
2000000
2500000
3000000
2006 2007 2008 2009 2010 2011 2012
Year
V
a
lu
e
 (
C
N
Y
)
Nifedipine Felodipine
Amiodipine Benazepril
Losartan Irbesartan
Valsartan Telmisartan
Atorvastatin Simvastatin
Metoprolol Bisoprolol
 
NB. We acknowledge the procurement of telmisartan was less than 1millionCNY/ year. However, 
included in view of the rapid rise in recent years  
 
However, there was a mixed picture regarding procurement prices for generics and originators 
among the principal 12 products over time (Table 3. More detailed analysis in Table 2A). In 
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general, procurement prices for both originators and generics decreased over time, although 
this was not universal.  
 
Table 3 ± Change in procurement expenditure/ unit (CNY) for 12 single originator and generic 
cardiovascular and cerebrovascular drugs in the Chongqing District between 2006 and 2012   
 
Product 2006 2007 2008 2009 2010 2011 2012
Metoprolol - Generic
Metoprolol - Originator 9.199 9.116 8.848 9.419 9.667 12.836 13.851
%LVRSURORO±*HQHULF
Bisoprolol - Originator 31.594 30.905 30.910 30.910 30.910 30.535 30.400
$PORGLSLQH±*HQHULF 32.048 35.975 36.962 37.892 38.661 38.346 38.668
$PORGLSLQH±2ULJLQDWRU 38.372 38.047 36.780 36.763 36.372 33.479 32.929
1LIHGLSLQH±*HQHULF 18.783 15.043 14.069 14.245 14.681 13.200 12.894
1LIHGLSLQH±RULJLQDWRU 34.385 34.018 33.500 33.500 33.476 31.256 31.130
)HORGLSLQH±*HQHULF 25.441 25.855 25.390 25.390 25.390 28.306 35.290
)HORGLSLQH±2ULJLQDWRU 36.120 34.569 34.153 34.137 33.787 32.690 32.500
%HQD]HSULO±*HQHULF 35.700 35.700 35.700 35.700 30.662 29.220
Benazepril - Originator 47.508 46.830 46.830 46.830 46.830 44.529 43.633
/RVDUWDQ±*HQHULF 66.080
/RVDUWDQ±2ULJLQDWRU 48.764 49.210 48.289 49.148 48.874 46.352 47.802
7HOPLVDUWDQ±*HQHULF 22.670 35.924 35.220 35.220 35.220 24.399 20.710
7HOPLVDUWDQ±2ULJLQDWRU 34.691 34.150 34.150 34.150 34.150 34.150 34.150
9DOVDUWDQ±*HQHULF 20.478 19.840 19.840 19.840 19.840 16.886 16.000
9DOVDUWDQ±2ULJLQDWRU 43.727 43.626 42.780 42.780 42.780 40.325 39.096
$WRUYDVWDWLQ±*HQHULF 34.148 30.789 30.090 30.090 31.175 28.938 28.964
$WRUYDVWDWLQ±2ULJLQDWRU 67.269 67.000 67.009 67.000 67.000 64.541 62.240
6LPYDVWDWLQ±*HQHULF 27.910 24.943 24.090 23.851 20.867 13.740 11.846
6LPYDVWDWLQ±2ULJLQDWRU 50.711 50.687 50.300 50.300 26.683 31.378 36.810
,UEHVDUWDQ±*HQHULF 22.960 22.950 22.950 22.950 19.271 18.340
,UEHVDUWDQ±2ULJLQDWRU 31.935 31.423 31.259 31.260 31.260 31.260 31.260  
 
Specific classes and products 
 
ȕ- Adrenergic receptor blockers 
Nogenerics were procured for either of the two higher volume beta blockers over time (Table 
2).  
 
There was an increase in the utilisation of esmolol hydrochloride injections during part of the 
study period. The main esmolol injection was launched in July 2006 with a specification of 0.1 
g × 1 ml priced 62.80 CNY per bottle. Only a limited amount was used: 788 bottles in 2006 and 
1,685 in 2007 (Figure 4). In April 2008 after the specification was adjusted to 0.2 g × 2 ml with 
a higher price of 116.52CNY, the procurement volume increased from 5,600 bottles in the first 
half of 2008 to 21,000 bottles in the first and second half of 2009. After its price decreased to 
68.84CNY per bottle, consumption decreased. This reduced to 1,150 bottles in the second half 
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of 2012, a 94.5% decrease from the peak. Concurrently, the utilization of both originator 
metoprolol and bisoprolol increased (Table 2 and 1A). 
 
Figure 4 ± Volume and procurement prices (CNY) of esmolol injections 2006 to 2012 in the 
Chongqing District 2006 to 2012 
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NB Specification of esomol injections were adjusted from 0.1 g × 1 ml to 0.2 g × 2 ml in April 2008 
 
Calcium channel blockers 
There was variable utilisation of generic versus originator calcium channel blockers. Utilisation 
of amlodipine and felodipine increased whilst utilisation of nifedipine decreased (Tables 2 and 
1A).  
 
There was increasing utilisation of both generic and originator amlodipine besylate (2.5mg x 
14 tablets) over time. However, there was no significant difference between the utilisation of 
either the generic or originator during the study period (P>0.05). 
 
There were generally stable pack prices during this period ((Figure 5, Tables 3 and 2A). 
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Figure 5 ± Procurement volume and prices (CNY) of generic besylate amlodipine (2.5mg 
besylate tablets x 14) 2006 to 2012 in the Chongqing District 
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There was decreasing utilisation of generic sustained release tablet nifedipine in the last half of 
2012. In the same period, procurement prices decreased (Figure 6). There was a 
corresponding increase in the consumption of the originator (Tables 2 and 1A). This led to a 
significant difference in the utilisation of originator vs. generic nifedipine during the course of 
the study (p<0.005 using the chi-square test). 
 
There was an overall 59% price differential (expenditure/ unit) for generic nifedipine vs. the 
originator by the second half of 2012 (Tables 3 and 2A). 
 
Figure 6 ± Procured price-volume of sustained release generic nifedipine 20 mg × 20 tablets in 
the Chongqing District of China 2006 to 2012 
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HMG Co-A reductase inhibitors (Statins) 
There was increased utilisation of both generic and originator atorvastatin and simvastatin 
over time (Tables 2 and 1A). Overall, there was low utilisation of generic vs. originator 
simvastatin at only 5% of total units during the past 2.5 years. Expenditure/ unit for generic 
simvastatin was only 34% and 25% originator prices in early 2006 and by the end of 2012 
respectively (Table 3 and 2A).  
 
There was high utilisation of generic atorvastatin versus total atorvastatin over time (Tables 2 
and 1A) compared with the situation for simvastatin. The procurement price for generic 
atorvastatin was 47% of the originator price in the last half of 2012 (Tables 3 and 2A). The 
price decline for generic atorvastatin was modest over time and there was no significant 
difference in the price changes for generic vs. originator atorvastatin between 2006 and 2012 
(p>0.05). 
 
Renin-angiotensin inhibiting drugs 
Generally, ARBs were more prescribed than ACEIs (Table 2). There was variable utilisation of 
generic renin-angiotensin inhibiting drugs over time (Tables 2 and 1A). The utilisation of 
generic irbesartan and telmisartan increased over the study period whilst the utilisation of 
generic valsartan remained low. Overall, there were no significant difference in the evolution of 
generic benazepril, irbesartan, and telmisartan versus originators between 2006 and 2012 
(Fischer exact test - p>0.05). 
 
Expenditure/ unit for generic telmisartan and generic valsartan in late 2012 was 41% and 64% 
respectively below early 2006 procurement prices, and expenditure/ unit for generic irbesartan 
in the second half of 2012 was 41% below pre-generic procurement prices (Tables 3 and 2A).  
The procurement price of enalapril maleate tablets moderated at the beginning of 2006 with 
similar consumption until 2010 (Figure 7). After its procurement price per unit decreased from 
CNY 22.08 to 13.04, utilisation also decreased. Later one of the manufacturers, Yangtze River 
Pharmaceuticals, changed its specification from 10 mg × 16 tablets to 10mg x 32 tablets 
combined with an increased price (CNY 25.30). The same overall volume was maintained 
based on the number tablets dispensed although the number of packages decreased. 
Concurrent with this, another manufacturer (Yabao Pharmaceuticals) lost much of its market 
share and stopped selling from February 2012. 
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Figure 7 ± Procurement price-volume of enalapril maleate tablets in the Chongqing District of 
China 2006 to 2012 
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Ligustrazine  
Ligustrazine injection was initially provided by four different manufacturers, and reached a 
peak of 46,400 bottles in 2007 before falling to 3,600 bottles in the first half of 2011 with 
procurement terminated in the second half of 2011. The procurement price decreased to CNY 
25.70 in the first half of 2009 and has been maintained at this price level (Figure 8). 
 
Figure 8 ± Procurement price and volume of ligustrazine injections (CNY) in Chongqing District 
2006 to 2012 
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Levocarnitine  
Expenditure on levocarnitine remained high throughout the 7-year period, at more than CNY 2  
million a year. The utilisation of levocarnitine powder for injection (1g) decreased appreciably 
after the procurement price almost halved from CNY 40.00 to 20.90. The price of the second 
preparation, levocarnitine injection 1 g × 5 ml, was only modestly reduced from CNY 51.48 to 
46.88 (Figure 9). This injection subsequently increased its utilisation at the expense of  the 
powder plus injection. 
 
Figure 9 - Price-volume of levocarnitine powder 1g and levocarnitine injection 1 g × 5 ml (CNY) 
2006 to 2012 in the Chongqing District 
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Oxiracetam  
Oxiracetam had the highest utilisation of any cardiovascular or cerebrovascular drug, 
increasing from 33.4 thousand units in 2006 to 139.6 thousand units in 2012 (Table 1). This 
was increasingly the injection (Figure 10), which had a higher relative price than the capsules.  
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Figure 10 - Price-volume of oxiracetam injection 1 mg × 5 ml in the Chongqing District of China 
2006 to 2012 
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Cinepazide  
There was appreciable fluctuation in the utilisation of cinepazide maleate injection during the 
study period as a result of neutropenia. This side-effect resulted in some countries refusing 
market authorisation; alternatively removing it from the market. The WHO also suggested 
compensating patients for adverse events caused by the drug [45,46]. During the study period, 
its procurement price remained relatively stable  
 
Traditional Chinese medicines 
There was a 4.41 fold increase in the utilisation of traditional Chinese medicines during the 
study period (Figure 1, Table 1). Three leading preparations currently account for 45% of the 
total market share of traditional Chinese medicines with a package price varying from CNY 
42.78 to135.96. High prices appear to be achieved and maintained with limited competition. 
The rising costs of Chinese materials contributed to these prices, especially at the end of 
2009. This resulted in procured expenditure/ unit for traditional Chinese medicines increasing 
from 23.41 CNY in the 2006 to 41.32 in 2012, corresponding to a 1.77 fold increase. As a 
result, procurement costs rose 7.78 fold. Some older products have now been transferred to 
community pharmacies where prices have fallen 
 
Discussion 
 
We will initially discuss utilisation and expenditure patterns in the Chongqing District including 
general findings as well as those for traditional Chinese medicines. Secondly, suggest the 
implications for the utilisation and expenditure for domestically produced products. Finally, we 
will suggest potential future reforms that could be considered by the authorities in China. 
These are based on successful measures among Western European countries, who have 
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already achieved equitable and comprehensive healthcare for their citizens. However, we are 
aware that any future demand-side measures will have only limited success unless the 
perverse incentives for physicians and hospitals are substantially reduced, e.g. addressing 
physician salaries who currently earn 5000 CNY (US$780) a month or less [42].  
 
Firstly, as expected, there was an appreciable increase in the utilisation and expenditure on 
medicines to treat cardiovascular and cerebrovascular diseases in the Chongqing District of 
China between 2006 and 2012 (Figures 1 and 2, Table 1). We believe this considerable 
increase can be attributed to many factors. These include urbanization, an aging population, 
the expanding scope of medical insurance and improving living standards. However, we are 
unable to comment further without specific research. This increase though mirrors the 
considerable increase in utilisation of statins and renin-angiotensin inhibiting drugs seen 
among Western European countries during the past decade [2-4,6,7,9-11,14-16] 
 
Authorities across countries have generally cut drug prices when faced with higher than 
expected expenditure or following a financial crisis [47-50]. China is no exception. The main 
measures introduced by the authorities to try and contain drug expenditure have been price 
reductions. This has been seen in practice especially for the generics apart from a minority of 
situations (Tables 3 and 2A), with some price reductions mirroring those among Western 
European countries [4,9,15]. However, price reduction polices implemented in isolation have 
not been effective in containing overall drug expenditure (Figure 2). These findings are similar 
to those of other authors in China [18,31,33] as well as other Asian countries. For instance in 
South Korea, policies concentrating on price controls without addressing demand-side 
measures did not achieve their desired result [49, 51].  
 
Secondly, we believe the considerable growth in the utilisation and expenditure on traditional 
Chinese medicines (Figures 1 and 2, Table 1) is an important finding. Traditional Chinese 
medicines accounted for 57% of total procured expenditure by the end of 2012. We believe 
this increase may have been facilitated by the launch of new products with higher prices, 
relatively limited competition, and the fact that these are typically administered by injection 
[29,31,41]. However, the lack of published data for many of these products, coupled with their 
high relative prices, suggests continued irrationality in prescribing in China despite the 
development of essential medicine lists [21].  
 
Concerns with irrationality in prescribing are further endorsed by the continued growth in the 
utilisation of originator medicines despite generics being available at reduced prices, which 
can be substantial (Tables 2 and 3, 1A and 2A). The reduction in the price of generics over 
time mirror some of those seen among Western European countries for ARBs and statins [1-5] 
when compared with earlier originator prices (Tables 3 and 2A). This suggests competition 
among generic companies has helped reduce procurement prices over time. However, 
hospitals and authorities will only realise the savings if this price reduction is accompanied by 
their appreciably increased utilisation where generics are available for procurement. Such 
activities could be facilitated by enforcement of the Prescription Management Ordinance in 
2007 specifying that prescriptions should be written by INN [18, 26], especially with recent 
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regulations improving the quality of generic medicines in China [21]. High voluntary INN 
prescribing rates of 98% to 99% have been achieved among a range of products and classes 
in Scotland through a variety of demand-side measures [2,9,10].  
 
Thirdly, we believe based on our findings that there appear to be four different models in 
operation for domestically produced pharmaceuticals (Table 5).  
 
Table 5 ± Four different models for domestically produced pharmaceuticals 
 
Model Details 
1 x A substantial drop in drug prices does appear to affect their subsequent use 
x This was illustrated by some products no longer purchased or with limited 
procurement after a significant price decline, e.g. generic nifedipine, enalapril of 
Yabao Pharmaceuticals, esmolol, levocarnitine powder for injection and 
ligustrazine (Figures 4, 6 to 9) 
x This was also illustrated by generic simvastatin - where there was limited use 
(Tables 2, 1A) versus the originator.  Alongside this, substantial procurement 
price reductions (67% over the study period) 
x The procurement price of the originator simvastatin also reduced over time but 
to a lesser extent (29%) (Tables 3 and 2A) 
x This may be attributable to the fact that higher prices may translate into higher 
profits and conversely lower prices with lower profits, with lower prices 
adversely affecting hospital profitability and physician salaries 
2 x A small decrease in the procured price per pack, e.g.10%, did not appear to 
generally change utilisation trends. There may also be an increase 
x We believe this was because the whole supply chain including manufacturers 
and prescribing doctors could adjust their profitability mix accordingly 
x This is illustrated by generic benazepril and telmisartan as well as both 
originator and generic atorvastatin with increased utilisation over time despite 
limited decreases in procurement expenditure/ unit (Tables 2 and 3, 1A and 2A) 
3 x Some drugs maintained a relatively high price during the study period and their 
consumption substantially increased, e.g. originator metoprolol and bisoprolol 
with the procurement price of metoprolol increasing during the study period 
(Tables 2 and 3, 1A and 2A) 
x This was also seen for oxiracetam  
x Other products with a relatively stable price over time also increased their 
volume in line with market growth, e.g. amlodipine besylate tablet (Figure 5) 
and cinepazide maleate injection (before its severe side effect became broadly 
known) 
4 x 7KHUHDSSHDUVWREHD³&1<SKHQRPHQRQ´LHZKHQWKHSURFXUHPHQWSULFH
per pack drops to near or below CNY 20, utilization rates usually decreased (or 
at least stopped increasing) 
x Examples include generic nifedipine (Figure 6), generic enalapril and generic 
simvastatin 
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Consequently, we believe we can speculate on drug utilisation patterns based on these 
combined findings. Traditional Chinese medicines have generally been preferred first for 
treatment. This is followed by originators and generics with relatively procurement high prices. 
One generic medicine in each class typically retains reasonable utilisation, e.g. amlodipine, 
atorvastatin and irbesartan (Table 2) among the calcium channel blockers, statins and ARBs 
respectively, although their volume might be lower than the originator. A substantial drop in 
prices subsequently adversely affects utilisation especially if prices drop to near or below CNY 
20 per pack (Table 5).  
 
However, we acknowledge that we will have to perform specific quantitative and qualitative 
research with defined hypotheses before we can provide specific guidance on drug utilisation 
patterns alongside changes in expenditure. 
   
With respect to the future, potential measures to enhance patient access to medicines without 
prohibitive increases in expenditure include enhancing INN prescribing as preciously 
described. They also include additional measures to further lower the price of generics given 
some of the low prices seen in Europe [2,3,7,10]. Alongside this, there must also be measures 
to enhance the rational use of medicines, which builds on the essential medicine list concept 
[21]. This includes encouraging the preferential prescribing of evidenced based low cost and 
equally effective generics versus more expensive originators. Another potential measure is to 
restrict prescribing choices within a class. As a result, enhance physician familiarity with the 
medicines they prescribe. This could potentially reduce adverse drug reactions and drug: drug 
interactions. This was the philosophy behind the generation of the Wise List in the Stockholm 
Healthcare Region, which contains approximately 200 drugs including first and second line 
choices covering most of the therapeutic needs in ambulatory care [52-54]. High adherence 
rates at 80 to 90%% to the voluntary Wise List are enhanced by the involvement of prescribers 
in the selection process, robust methodologies for selecting the drugs based principally on 
published evidence of effectiveness and safety, a comprehensive communication programme 
including a separate Wise List for both patients and physicians, physician trust in the guidance 
as well as regular feedback [52-55]. Research findings have also shown that increased 
adherence to the Wise List also reduces costs since medicines that have the most robust data 
tend to be well established medicines [52,55,56]. There are similar examples in Spain and 
Scotland [9,10,53].  
 
Other initiatives include potentially introducing prescribing quality indicators, which are 
increasingly used in healthcare as a tool to achieve safe and quality clinical care and 
cost-effective therapy, as well as for professional learning, remuneration, and accreditation 
along with financial incentives [56-60]. Any developed indicators must have (a) content validity; 
(b) face validity, i.e. relevance, credibility & acceptability (c); concurrent validity ± compared 
with the gold standard (d) construct validity ± theoretical construct of quality and (e) predictive 
validity to be effective and sustainable in practice [61]. 
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We are already seeing a reduction in the procurement of traditional Chinese Medicines in the 
Chongqing District. This will now be monitored, along with the introduction of potential 
suggestions to further enhance the rational use of medicines. This includes addressing current 
perverse incentives. As a result, ascertain whether any additional measures are still needed in 
the future in China to further enhance access to medicines without significantly increasing 
overall expenditure.  
 
We acknowledge there are some limitations in this research. These include the fact that the 
utilisation and procurement data was collected from just one leading hospital in one District in 
China. In addition, we did not use DDDs for the reasons stated. However, we are aware that 
other authors have not always used DDDs in this type of research. For instance, Hoyle used a 
market share weighted average price to analyse cost-effectiveness [62], and Danzon and Kim 
defined standard units as one tablet, one capsule, or one gram, to compare the price of 
products in different life cycles [63]. Despite these limitations, we believe our findings are 
robust and transferable across hospitals and drug classes given our choice of hospital and our 
methodology based on actual procurement data. However, we acknowledge that follow-up 
studies will be needed in this and other Districts to substantiate some of the findings. 
 
Conclusions 
 
Traditional Chinese medicines have occupied the largest market share by volume and 
expenditure in this District, with originators from multinational companies preferred to generics 
from local manufacturers in view of their relatively higher price. The findings also suggest that 
price alterations had an appreciable influence on subsequent utilisation patterns, especially 
when these were significantly decreased. However, further research is needed in this area 
before we can make any definitive statements. We do believe a number of measures are 
needed in China to moderate future growth of pharmaceutical expenditure whilst expanding 
healthcare access. Authorities must seek to enhance the rational use of medicines as well as 
address some of the barriers. These include addressing the current perverse incentives. This 
already appears to be happening with a recent reduction in the procurement of traditional 
Chinese medicines. Suggested measures also include greater encouragement of INN 
prescribing build on experiences among European countries. 
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Appendix 
 
Table 1A ± Utilisation of both generics and originators for 12 single cardiovascular products in 
the Chongqing District between 2006 to 2012 
 
Product 1H 2006 2H 2006 1H 2007 2H 2007 1H 2008 2H 2008 1H 2009 2H 2009 1H 2010 2H 2010 1H 2011 2H 2011 1H 2012 2H 2012
Beta Blockers
Metoprolol - Generic 0 0 0 0 0 0 0 0 0 0 0 0 0 0
*Metoprolol - Originator 9660 12977 13251 15051 17040 16640 18000 19920 22800 23280 26710 37440 51840 50400
%LVRSURORO±*HQHULF 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Bisoprolol - Originator 4020 4380 7200 6840 8460 9840 7200 10405 15480 18900 19260 17460 20880 19980
Total beta blockers 13680 17357 20451 21891 25500 26480 25200 30325 38280 42180 45970 54900 72720 70380
Calcium Channel blockers
$PORGLSLQH±*HQHULF 4245 5200 8600 8570 9400 11800 15210 18940 23900 23670 30708 29900 31440 35070
$PORGLSLQH±2ULJLQDWRU 5100 2800 4500 4400 4200 5400 7866 11600 12000 14200 14900 10800 15600 26250
1LIHGLSLQH±*HQHULF 13509 11750 12767 13361 14600 13900 14600 13830 13900 13200 14400 15200 13800 3300
1LIHGLSLQH±RULJLQDWRU 5400 6480 9120 9530 19201 12420 15390 9990 21240 18090 18540 18630 27000 28620
)HORGLSLQH±*HQHULF 8 240 340 780 280 800 550 500 450 490 50 200 340 900
)HORGLSLQH±2ULJLQDWRU 2160 480 2400 4270 6317 6240 9600 10080 16464 13380 16960 19200 28560 24720
Total calcium channel blockers 30422 26950 37727 40911 53998 50560 63216 64940 87954 83030 95558 93930 116740 118860
Total generics 17762 17190 21707 22711 24280 26500 30360 33270 38250 37360 45158 45300 45580 39270
% generics 58 64 58 56 45 52 48 51 43 45 47 48 39 33
Renin-angiotensin inhibitors
%HQD]HSULO±*HQHULF 329 1080 650 200 3180 7480 7330 6240 6700 8160 7440
Benazepril - Originator 3600 2880 3520 5040 3600 7680 7560 9000 8640 9000 11460 13560 14700 16199
,UEHVDUWDQ±*HQHULF 700 4300 7000 8600 10000 15565 10170 8000 11800 11000 14000
,UEHVDUWDQ±2ULJLQDWRU 3050 3600 6700 4800 7156 5530 7880 12640 15120 17800 16920 17280 21960 21240
/RVDUWDQ±*HQHULF 1400 3200
/RVDUWDQ±2ULJLQDWRU 2760 3400 5000 5990 8000 9800 14500 8830 21800 16800 14600 21600 20800 16820
7HOPLVDUWDQ±*HQHULF 252 150 1350 2753 2559 2800 2800 3600 4000 5000 4800 5575 5600
7HOPLVDUWDQ±2ULJLQDWRU 982 600 1150 2437 4000 4400 5530 3400 6700 4900 5448 9400 14200 12000
9DOVDUWDQ±*HQHULF 614 200 500 700 400 450 600 750 450 800 500 775 950
9DOVDUWDQ±2ULJLQDWRU 600 1166 540 3710 6744 7665 9450 11580 11520 12480 17060 23080 28800 30080
Total renin-angiotensin inhibitors 11858 11846 17560 25056 37633 45684 56970 62030 91175 82930 85528 108720 127370 127529
Total generics 866 200 650 3079 8133 10609 12050 16580 27395 21950 20040 23800 26910 31190
% generics (all) 7 2 4 12 22 23 21 27 30 26 23 22 21 24
% generic benazapril vs. all benazepril 6 23 8 3 26 46 45 35 33 36 31
% generic irbesartan vs all irbesartan 0 0 0 13 38 56 52 44 51 36 32 41 33 40
% generic telmisartan 20 0 12 36 41 37 34 45 35 45 48 34 28 32
Statins
$WRUYDVWDWLQ±*HQHULF 3840 3840 4080 4320 4460 4498 5040 6720 11039 16620 24480 33040 40010 49783
$WRUYDVWDWLQ±2ULJLQDWRU 720 1200 1680 840 2455 2884 8200 12600 13920 17520 17760 16400 17520 24762
6LPYDVWDWLQ±*HQHULF 268 116 96 300 912 1140 2736 1980 2640 1780 1760 1440 960 720
6LPYDVWDWLQ±2ULJLQDWRU 1950 5260 7805 7799 15600 15800 15800 18520 31200 32600 31600 29200 20000 18600
Total Statins 6778 10416 13661 13259 23427 24322 31776 39820 58799 68520 75600 80080 78490 93865
Total generics 4108 3956 4176 4620 5372 5638 7776 8700 13679 18400 26240 34480 40970 50503
% generics 61 38 31 35 23 23 24 22 23 27 35 43 52 54
Total all products 62738 66569 89399 101117 140558 147046 177162 197115 276208 276660 302656 337630 395320 410634
Total generics 22736 21346 26533 30410 37785 42747 50186 58550 79324 77710 91438 103580 113460 120963
% generics 36 32 30 30 27 29 28 30 29 28 30 31 29 29  
NB. Utilisation measured in package units, * = 2 Specifications; ** = several manufacturers and 
specifications. ***= Different specification to the originator. 1H = first half of the year; 2H = second half of 
the year 
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Table 2A ± Change in procurement expenditure/ unit (CNY) for 12 single originator and 
generic cardiovascular and cerebrovascular drugs in the Chongqing District between 2006 and 
2012   
Product 1H 2006 2H 2006 1H 2007 2H 2007 1H 2008 2H 2008 1H 2009 2H 2009 1H 2010 2H 2010 1H 2011 2H 2011 1H 2012 2H 2012 % change
2H 2012 % vs. pre-
originator loss 
prices
% difference generic 
2H 2012 generic vs. 
originator 1H2006
*Metoprolol - Originator 10.02 8.59 8.67 9.51 8.68 9.02 9.22 9.60 9.70 9.63 12.72 12.92 13.92 13.78 37
Bisoprolol - Originator 32.35 30.90 30.90 30.91 30.91 30.91 30.91 30.91 30.91 30.91 30.63 30.43 30.40 30.40 -6
 ? ?ŵůŽĚŝƉŝŶĞ ?'ĞŶĞƌŝĐ 32.77 31.46 34.56 37.40 36.94 36.98 37.21 38.44 39.11 38.20 38.32 38.37 38.19 39.10 19 0
ŵůŽĚŝƉŝŶĞ ?KƌŝŐŝŶĂƚŽƌ 39.03 37.17 36.83 39.29 36.78 36.78 36.77 36.76 36.78 36.03 33.73 33.13 33.13 32.81 -16
EŝĨĞĚŝƉŝŶĞ ?'ĞŶĞƌŝĐ 19.31 18.18 15.85 14.27 14.43 13.69 14.38 14.10 14.74 14.61 13.58 12.84 12.91 12.84 -34 -64
EŝĨĞĚŝƉŝŶĞ ?ŽƌŝŐŝŶĂƚŽƌ 35.45 33.50 33.50 34.51 33.50 33.50 33.50 33.50 33.50 33.45 31.38 31.13 31.13 31.13 -12
&ĞůŽĚŝƉŝŶĞ ?'ĞŶĞƌŝĐ 14.68 25.80 25.80 25.88 25.39 25.39 25.39 25.39 25.39 25.39 25.39 29.04 35.29 35.29 140 -3.4
&ĞůŽĚŝƉŝŶĞ ?KƌŝŐŝŶĂƚŽƌ 36.55 34.20 34.20 34.78 34.20 34.11 34.07 34.20 33.99 33.54 33.12 32.31 32.50 32.50 -11
ĞŶĂǌĞƉƌŝů ?'ĞŶĞƌŝĐ 35.70 35.70 35.70 35.70 35.70 35.70 35.70 32.21 29.22 29.22 29.22 -18 -38
Benazepril - Originator 48.05 46.83 46.83 46.83 46.83 46.83 46.83 46.83 46.83 46.83 45.16 44.00 44.00 43.30 -10
/ƌďĞƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 22.96 22.95 22.95 22.95 22.95 22.95 22.95 20.65 18.34 18.34 18.34 -41
/ƌďĞƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 32.73 31.26 31.26 31.65 31.26 31.26 31.26 31.26 31.26 31.26 31.26 31.26 31.26 31.26
>ŽƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 66.08 66.08 0 42
>ŽƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 49.29 48.34 48.44 49.85 48.25 48.32 49.30 48.89 49.72 47.78 45.93 46.63 45.93 50.11 2
dĞůŵŝƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 22.67 35.22 36.00 35.22 35.22 35.22 35.22 35.22 35.22 28.11 20.53 20.71 20.71 -9 -41
dĞůŵŝƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 35.02 34.15 34.15 34.15 34.15 34.15 34.15 34.15 34.15 34.15 34.15 34.15 34.15 34.15 -2
sĂůƐĂƌƚĂŶ ?'ĞŶĞƌŝĐ 20.69 19.84 19.84 19.84 19.84 19.84 19.84 19.84 19.84 17.44 16.00 16.00 16.00 -23 -64
sĂůƐĂƌƚĂŶ ?KƌŝŐŝŶĂƚŽƌ 44.60 43.28 42.78 43.75 42.78 42.78 42.78 42.78 42.78 42.78 41.10 39.75 39.60 38.61 -13
 ? ? ?ƚŽƌǀĂƐƚĂƚŝŶ ?'ĞŶĞƌŝĐ 35.09 33.21 31.00 30.59 30.09 30.09 30.09 30.09 30.09 31.90 30.14 28.05 28.92 29.00 -17 -57
ƚŽƌǀĂƐƚĂƚŝŶ ?KƌŝŐŝŶĂƚŽƌ 67.72 67.00 67.00 67.00 67.00 67.02 67.00 67.00 67.00 67.00 66.67 62.24 62.24 62.24 -8
^ŝŵǀĂƐƚĂƚŝŶ ?'ĞŶĞƌŝĐ 28.07 27.54 25.81 24.67 24.09 24.09 24.09 23.52 21.74 19.57 13.74 13.74 13.74 9.32 -67 -82
^ŝŵǀĂƐƚĂƚŝŶ ?KƌŝŐŝŶĂƚŽƌ 51.82 50.30 50.30 51.07 50.30 50.30 50.30 50.30 26.70 26.67 26.62 36.53 36.81 36.81 -29  
NB. * = 2 Specifications; ** = several manufacturers and specifications. ***= Different specification to the 
originator. 1H = first half of the year; 2H = second half of the year 
 
